טוען...
Arylacetamide Deacetylase Is Involved in Vicagrel Bioactivation in Humans
Vicagrel, a structural analog of clopidogrel, is now being developed as a thienopyridine antiplatelet agent in a phase II clinical trial in China. Some studies have shown that vicagrel undergoes complete first-pass metabolism in human intestine, generating the hydrolytic metabolite 2-oxo-clopidogrel...
שמור ב:
| הוצא לאור ב: | Front Pharmacol |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Frontiers Media S.A.
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5701912/ https://ncbi.nlm.nih.gov/pubmed/29209217 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2017.00846 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|